DDInter1702 DDInter1840
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Sorafenib {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) binds {v} (Gene) RAF1
RAF1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) downregulates {v} (Gene) BAG3
BAG3 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) downregulates {v} (Gene) DAG1
DAG1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) binds {v} (Gene) MAPK15
MAPK15 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} (Compound) upregulates {v} (Gene) GRB10
GRB10 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Vandetanib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sorafenib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Sorafenib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Sorafenib (Compound) binds RAF1 (Gene) and RAF1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib (Compound) downregulates DAG1 (Gene) and DAG1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib (Compound) binds MAPK15 (Gene) and MAPK15 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib (Compound) upregulates GRB10 (Gene) and GRB10 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)